Thumbnail

CHRONIC STABLE ANGINA MARKET - PIPELINE INTELLIGENCE, 2019

Looking to buy the report?

Introduction

Angina refers to chest pain. The chest pains are very common in hospital settings, particularly emergency department. It usually gets triggered by emotional stress, heavy meals with indigestion, smoking, and sudden exposure to very hot or cold temperatures. Cardiovascular diseases (CVDs) are the major cause of death and disability, worldwide. An estimated 30% of global deaths are due to CVDs, which include nearly 18 million people worldwide. As per the Nesia Foundation Hospital, globally, about 14.2 million people, between the age group 30 and 69 years, die prematurely from lifestyle disorders. Further, as per the Gilead report, in collaboration with the American College of Cardiology, each year, about 13 million US citizens have coronary artery disease and, among them, 9 million have chest pain. These lead to demand for several beta blockers in combination therapies, nitrate-based drugs, and other calcium channel antagonists.

Report Coverage

This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases and status of clinical trials across major regions of the world are provided, with data obtained from multiple sources. The report also comprises of a list of key sponsors having pipeline products for the concerned market.

Chronic Stable Angina Clinical Trial Analysis, by Phase and Status

  • The clinical trial analysis for chronic stable angina indicates that there are around XX number of trials under various phases
  • Phase X trials accounted for the majority share
  • The trial data analysis suggests a number of ongoing trials and the ones terminated

Chronic Stable Angina Clinical Trials Analysis, by Geography

  • By geography, the scope of the report covers the regional assessment for the clinical trials, globally. It covers concise information of registered clinical trials, in different countries, across several developed and emerging markets
  • Over the last decade, there has been a continuous rise in the prevalence of several chronic diseases, which, in several cases, leads to heart-related diseases. Some of the major chronic diseases include cancer, kidney failure, and heart diseases, among others. Such factors drive the importance of advances in the development of angina-based drugs

Key Sponsors in Chronic Stable Angina CHRO Clinical Trials

The report will cover analysis on trails and information on key sponsors, companies, and researchers.

Research Methodology

Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and in-house team of research experts. The pipeline assessment reports are generated, based on the information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research are validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports are continuously updated, to incorporate the most relevant and authentic information to our clients.

Reasons to buy the Report

This report will help you understand

  • The number of clinical trials that are being conducted worldwide.
  • The key products that are under development (Phase I, Phase II, and Phase III).
  • The main areas of research under development (by product, mechanism of action, molecule, delivery, etc.).
  • The average recruitment size in trials.
  • Key deals between institutions and industries.
  • Gather insights on regional and country-level data.
  • Review of dormant and discontinued studies across the category.
  • Information on key sponsors and profiles.
  • Protocol and design comparisons, to generate the best solution for your product development strategy.

1. Introduction

2. Research Methodology

3. Disease Epidemiology and Trends

4. Healthcare Expenditure and R&D Trends

5. Executive Summary

6. Clinical Trials Segmentation, by Phase

                6.1 Phase-III Product Candidates

                6.2 Phase-II Product Candidates

                6.3 Phase-I Product Candidates

7. Clinical Trials, Segmentation, by Status

                7.1 Suspended

                7.2 Terminated

                7.3 Withdrawn

                7.4 Ongoing

                7.5 Completed

                7.6 Other Statuses

8. Pipeline Therapeutic Assessment (Infographic Charts and Brief description)

                8.1. By Clinical Phase and Molecule Type

                8.2. By Clinical Phase and Route of Administration

                8.3 By Sponsor/Collaborator/Institutions

                8.4 By Geography

9. Market Updates

10. Key Sponsor Profiles

11. Sources and Disclaimer

12. About Mordor Intelligence

Looking to buy the report?

Need a report that reflects how COVID-19 has impacted this market and its growth?

Looking to customize report?

Email

Message

By submitting, you confirm that you agree to our privacy policy